Paper

Tree Display

AceDB Schema

XML Display

Feedback

Paper Report for: Ait-Tihyaty_2013_Invest.New.Drugs_31_1409

Reference

Title: ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ
Ref: Invest New Drugs, 31:1409, 2013 : PubMed

        



Related information

Substrate | Capecitabine,


Citations formats

Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ (2013)
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
Invest New Drugs 31: 1409-23

Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ (2013)
Invest New Drugs 31: 1409-23



Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page
webmaster

Acknowledgements and disclaimer